Curanex Pharmaceuticals Inc
CURX
$0.32
-$0.01-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 332.30% | 135.16% | 163.27% | 261.06% | 1,396.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,359.75% | 429.17% | 163.27% | 261.06% | 1,396.91% |
| Operating Income | -1,359.75% | -429.17% | -163.27% | -261.06% | -1,396.91% |
| Income Before Tax | -1,068.77% | -468.51% | -217.29% | -335.45% | -1,773.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,068.77% | -468.51% | -217.29% | -335.45% | -1,773.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,068.77% | -468.51% | -217.29% | -335.45% | -1,773.06% |
| EBIT | -1,359.75% | -429.17% | -163.27% | -261.06% | -1,396.91% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 20.60% | 76.75% | 71.25% | 59.01% | -503.43% |
| Normalized Basic EPS | 19.70% | 77.56% | 72.27% | 60.14% | -499.00% |
| EPS Diluted | 20.60% | 76.75% | 71.25% | 59.01% | -503.43% |
| Normalized Diluted EPS | 19.70% | 77.56% | 72.27% | 60.14% | -499.00% |
| Average Basic Shares Outstanding | 122.47% | 1,800.60% | 2,062.76% | 2,784.84% | 1,809.84% |
| Average Diluted Shares Outstanding | 122.47% | 1,800.60% | 2,062.76% | 2,784.84% | 1,809.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |